Terumo Pharmaceutical Solutions

Terumo Announces Completion of Acquisition of WuXi Biologics Drug Product Plant in Leverkusen, Germany

Terumo Corporation (TSE: 4543) today announced the successful completion of its acquisition of a Drug Product Plant and associated Quality Control Laboratory operations from WuXi Biologics in Leverkusen, Germany with the transaction officially closing on September 30, 2025. This strategic acquisition reinforces Terumo's position in the Contract Development and Manufacturing Organization (CDMO) sector, expands its integrated...

TERUMO ANNOUNCES COMMERCIAL LAUNCH OF THE IMMUCISE INTRADERMAL INJECTION SYSTEM

Terumo Corporation today announced the commercial launch of its Immucise Intradermal Injection System, which is designed to deliver vaccines and other approved drugs to the dermal layer of the skin, with the potential for vaccines to improve immunogenicity in comparison to subcutaneous and intramuscular injection. The Immucise Intradermal Injection System is a vertical puncture type...

Terumo Launches its Injection Filter Needle, a first step of the INFINO™ -Development Program, to extend the choice for hypodermic and intravitreal injections

​15 January 2024 – Leuven, Belgium – Terumo Corporation (TSE: 4543) today announced the global launch of the Terumo Injection Filter Needle, a first step of the INFINO™ -Development Program. Indicated for hypodermic as well as for intravitreal injections, the Injection Filter Needle features an integrated polyamide 5 micrometer mesh filter to prevent particles from being injected.​ Developed to extend the...
2-44-1 Hatagaya, Shibuya-ku, Tokyo

+81-3-3374-8111